Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
The award recognizes powerful science–industry collaborations for social good
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
